Trials / Completed
CompletedNCT00253331
Lab Study of MQX-503 in Treatment of Raynaud's
Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 36 (planned)
- Sponsor
- MediQuest Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phenomenon, follwoing exposure to cold temperatures. Blood flow is determined by scanning laser Doppler equipment and skin temperature is measured using attached thermistor probes. Following baseline measurements, the study gel is applied, the hand is placed in a cold chamber, and then blood flow and skin temperature are monitored for the next two hours. Each patient will receive multiple doses on different days so that each can serve as his/her own control in interpreting the response.
Conditions
- Raynaud Disease
- Raynaud Disease Secondary to Scleroderma
- Raynaud Secondary to Other Autoimmune Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | topical organogel with nitroglycerin |
Timeline
- Start date
- 2004-11-01
- Completion
- 2005-09-01
- First posted
- 2005-11-15
- Last updated
- 2007-05-30
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00253331. Inclusion in this directory is not an endorsement.